Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04267848 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04267848 · ClinicalTrials.gov record · last posted 2026-08-27

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

StatusRecruiting
PhasePhase 3
Started2020-06-16
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Amendment record 967 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 967 times since 2020-02-12; most recent amendment 2026-07-24. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-03-19
Status change Suspended→Recruitingv227
2021-10-23
Status change Recruiting→Suspendedv205
2020-06-19
Status change Not Yet Recruiting→Recruitingv7
Trial Details
NCT Number NCT04267848
Lead Sponsor National Cancer Institute (NCI)
Conditions Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Enrollment 1,210 participants
Start Date 2020-06-16
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-27